Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors
Related Experiment Video
Updated: Aug 26, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Yuta Doi1, Hiroaki Tagaya1, Ayaka Noge1
1Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo, 162-8480, Japan.
Background:
Chromosomal aberrations involving the anaplastic lymphoma kinase (ALK) gene have been observed in approximately 4% of patients with non-small cell lung cancer (NSCLC). Although these patients clinically benefit from treatment with various ALK tyrosine kinase inhibitors (ALK-TKIs), none of these can inhibit the development of resistance mutations. Considering inevitable drug resistance and the variety of available ALK-TKIs, it is necessary to predict the pattern of drug-resistance mutations to determine the optimal treatment strategy.
Objective:
We aimed to establish a polymerase chain reaction (PCR)-based system to predict the development of resistance mutations against ALK-TKIs and identify therapeutic strategies using the upcoming ALK-TKIs repotrectinib (TPX-0005) and ensartinib (X-396) following recurrence on first-line alectinib treatment for ALK-positive NSCLC.
Methods:
An error-prone PCR-based method for predicting drug resistance mutations was established and the half-maximal inhibitory concentration (IC50) values of the predicted ALK mutations were evaluated in a Ba/F3 cell-based assay.
Results:
We predicted several resistance mutations against repotrectinib and ensartinib, and demonstrated that the next-generation ALK-TKI TPX-0131, was active against repotrectinib-resistant mutations and that the FLT3 inhibitor gilteritinib was active against ensartinib-resistant mutations.
Conclusions:
We developed a PCR-based system for predicting drug resistance mutations. When this system was applied to repotrectinib and ensartinib, the results suggested that these drugs can be used for the second-line treatment of ALK-positive NSCLC. Predicting resistance mutations against TKIs will provide useful information to aid in the development of effective therapeutic strategies.
Insights
A new PCR-based system predicts anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) resistance mutations in non-small cell lung cancer (NSCLC). This aids in selecting optimal treatments like repotrectinib and ensartinib for resistant ALK-positive NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) gene rearrangements occur in ~4% of non-small cell lung cancer (NSCLC) patients.
- ALK tyrosine kinase inhibitors (TKIs) are effective but resistance mutations inevitably develop.
- Predicting resistance patterns is crucial for optimizing treatment strategies in ALK-positive NSCLC.
Purpose of the Study:
- To develop a polymerase chain reaction (PCR)-based system for predicting ALK-TKI resistance mutations.
- To evaluate therapeutic strategies using novel ALK-TKIs repotrectinib and ensartinib after alectinib resistance.
- To identify effective treatments for ALK-positive NSCLC with acquired resistance.
Main Methods:
- Established an error-prone PCR method to predict drug resistance mutations.
- Assessed half-maximal inhibitory concentration (IC50) values of predicted ALK mutations in a Ba/F3 cell assay.
- Evaluated the efficacy of repotrectinib, ensartinib, TPX-0131, and gilteritinib against resistant mutations.
Main Results:
- Several resistance mutations against repotrectinib and ensartinib were predicted.
- The next-generation ALK-TKI TPX-0131 showed activity against repotrectinib-resistant mutations.
- The FLT3 inhibitor gilteritinib demonstrated activity against ensartinib-resistant mutations.
Conclusions:
- A PCR-based system for predicting drug resistance mutations was successfully developed.
- Repotrectinib and ensartinib show potential as second-line treatments for ALK-positive NSCLC.
- Predicting TKI resistance mutations is vital for developing effective therapeutic strategies in NSCLC.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
